NCT07535632 2026-04-17
BEST
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
Clinical Trials
19 trialsNCT04104139 2026-04-15
TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer
OHSU Knight Cancer Institute
Phase 1 Active not recruiting
NCT04920032 2026-04-13
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
University of California, Irvine
Phase 1 Recruiting
NCT05927857 2026-04-09
Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .
National Health Research Institutes, Taiwan
Phase 1/2 Recruiting
NCT07491159 2026-03-24
Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2 Active not recruiting
NCT03223779 2026-03-12
Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
Massachusetts General Hospital
Phase 1/2 Completed
NCT05343013 2026-03-06
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04511039 2026-03-02
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT07318389 2026-02-27
ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Not yet recruiting
NCT04109924 2026-02-10
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Roswell Park Cancer Institute
Phase 2 Completed
NCT07371871 2026-01-28
A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer
Anhui Provincial Cancer Hospital
Phase NA Not yet recruiting
NCT07286695 2026-01-21
Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT03844620 2026-01-09
Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07261709 2025-12-03
Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07212933 2025-10-08
RAK in GC
Chinese PLA General Hospital
Phase 2 Recruiting
NCT07085169 2025-07-25
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
Ruijin Hospital
Phase 2 Recruiting
NCT05508737 2025-07-11
Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer
Yonsei University
Phase 1/2 Active not recruiting
NCT05201352 2025-05-30
TASKIN
Centre Georges Francois Leclerc
Phase 1/2 Active not recruiting
NCT06992648 2025-05-28
REGTAS-2
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3 Recruiting